Literature DB >> 6956376

Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study.

M P Sullivan, T Chen, P G Dyment, E Hvizdala, C P Steuber.   

Abstract

The efficacy of intrathecal (i.t.) chemoprophylaxis was compared with cranial radiotherapy plus i.t. methotrexate (MTX) in a Southwest Oncology Group (SWOG) study accessing 408 patients from September 10, 1974, to October 29, 1976. Randomization was stratified by prognostic groups (PGs) based on age and white blood cell count at diagnosis. All received induction therapy with vincristine and prednisone (Pred); maintenance therapy consisted of daily 6-mercaptopurine and weekly MTX. Consolidation for arm 1 employed cyclophosphamide and L-asparaginase followed by biweekly 5-day courses of parenteral MTX. The first dose of each course of MTX was given i.t. in triple chemoprophylaxis (MTX, hydrocortisone, and cytosine arabinoside). During maintenance, i.t. chemoprophylaxis was bimonthly and 28-day Pred "pulses" were given every 3 mo. Arm 2 i.t. chemoprophylaxis was initiated on achievement of remission, and arm 3 i.t. on treatment day 1; both continued 1 yr. Arm 4 induction included two doses of L-asparaginase. On achievement of remission, CNS prophylaxis (radiotherapy, 2400 rad plus i.t. MTX) was given. For all, therapy was discontinued after 3 yr of continuous complete remission. Survival and the incidence of extramedullary relapse were similar for the treatments employing either i.t. chemoprophylaxis or radiotherapy plus i.t. MTX upon achievement of remission. Among poor prognosis patients, the duration of complete remission was significantly better with the regimen using i.t. chemoprophylaxis as a component of consolidation therapy than with the regimen employing i.t. chemoprophylaxis early in induction or with the treatment using radiotherapy plus i.t. MTX for CNS prophylaxis. In poor prognosis patients, the initiation of i.t. chemoprophylaxis during consolidation was also associated with hematologic remissions that were significantly better than those achieved with the treatment employing early CNS chemoprophylaxis or with the regimen using radiotherapy plus i.t. MTX. Among average prognosis patients, therapy with CNS chemoprophylaxis during consolidation, as well as the regimen employing radiotherapy and i.t. MTX for CNS prophylaxis, produced hematologic remissions that were significantly longer than those obtained with the regimen using early CNS chemoprophylaxis. Hematologic remissions of good prognosis patients who received treatment with the regimen employing i.t. chemoprophylaxis during consolidation were statistically superior when compared to the regimen employing CNS radiotherapy plus i.t. MTX. This study indicates that i.t. chemoprophylaxis may be substituted for cranial radiotherapy when utilizing effective systemic regimens. Additionally, chemoprophylaxis may be reduced from 3 to 1 yr in patients with good prognostic factors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6956376

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  An adolescent with suspected intracranial hypertension - ALL is not what it seems.

Authors:  Asgeir Store Jakola; Sasha Gulati
Journal:  Childs Nerv Syst       Date:  2012-01-28       Impact factor: 1.475

Review 2.  A 50-year journey to cure childhood acute lymphoblastic leukemia.

Authors:  Ching-Hon Pui; William E Evans
Journal:  Semin Hematol       Date:  2013-07       Impact factor: 3.851

3.  Milestones in the curability of pediatric cancers.

Authors:  Melissa M Hudson; Michael P Link; Joseph V Simone
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

4.  Cranial irradiation in childhood lymphoblastic leukemia: time for reappraisal.

Authors:  J M Chessells
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-14

Review 5.  Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.

Authors:  Melissa M Hudson; Joseph P Neglia; William G Woods; John T Sandlund; Ching-Hon Pui; Larry E Kun; Leslie L Robison; Daniel M Green
Journal:  Pediatr Blood Cancer       Date:  2011-10-28       Impact factor: 3.167

Review 6.  Paediatrics--Part II.

Authors:  B L Priestley; C J Harrison; M P Gerrard; A Gibson
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

7.  Current issues in the management of children with acute lymphocytic leukaemia.

Authors:  D Pinkel
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

8.  Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.

Authors:  Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Veronika Northrup; Lu Chen; Megan Nicoletti; Bruce Bostrom; Linda Stork; Joseph P Neglia
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  Recent experience with intensive combination chemotherapy for treatment of childhood acute lymphoblastic leukaemia.

Authors:  E Vandenberghe; A Staines; F Breatnach; A O'Meara
Journal:  Ir J Med Sci       Date:  1989-05       Impact factor: 1.568

10.  Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-term follow up with cerebral computed tomography scans and endocrinological studies.

Authors:  H Hasle; J Helgestad; J K Christensen; B B Jacobsen; J Kamper
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.